-
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
21 Oct 2025 12:20 GMT
… -1 trial for social anxiety failed to meet endpoints.
Citius Pharmaceuticals Inc … .35 in pre-market trading.
Theravance Biopharma Inc (NASDAQ:TBPH) fell … data from Phase 1 clinical trial evaluating PCRX-201, gene therapy …
-
Theravance stands up nOH physician education campaign ahead of pivotal data
21 Oct 2025 00:23 GMT
… brain disorder. According to Theravance, 70% to 90% of … the activities in August.
Theravance is educating physicians and … quarter of 2026. Theravance plans to seek FDA approval if the … trial in a broader population missed its primary endpoint. Theravance …
-
Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease
30 Sep 2025 08:20 GMT
… Novartis, Oncodesign Precision Medicine, ONO Pharma, OSE … Satisfay, Takeda, Telavant, Theravance, Thermo Fischer, Tigenix, … treatments to monoclonal antibodies and future drug delivery systems. Pharmaceutics … activated glycans. Biotechnol Bioeng. 2006; …
-
Fully Enrolled CYPRESS Phase 3 Trial to Test Ampreloxetine in Symptomatic Neurogenic Orthostatic Hypotension of MSA
28 Aug 2025 12:57 GMT
… first randomized-withdrawal trial designed specifically for … include use of prohibited medications (MAOIs, strong CYP1A2 … changes to orthostatic hypotension treatment, substance abuse, uncontrolled … .
REFERENCES
1. Theravance Biopharma Completes Enrollment …
-
Theravance Biopharma Completes Phase III CYPRESS Trial Enrollment for Novel Norepinephrine Reuptake Inhibitor in Multiple System Atrophy
25 Aug 2025 19:05 GMT
… measure treatment impact.
Regulatory Pathway and Next Steps: Theravance … professor of Medicine, NYU Grossman School of Medicine, in a … first randomized-withdrawal trial designed specifically for the … expedited New Drug Application submission to the FDA with …
-
Theravance Biopharma completes enrollment in pivotal phase 3 CYPRESS study of ampreloxetine in patients with symptomatic nOH due to MSA
26 Aug 2025 12:30 GMT
… the first randomized-withdrawal trial designed specifically for the … planning to request priority FDA review, if data are … an Orphan Drug Designation for ampreloxetine for the treatment of …
Theravance Biopharma, Inc.'s focus is to deliver Medicines …
-
Pneumococcal Infections Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight
21 Aug 2025 17:00 GMT
… and Drug Administration (FDA) … . Treatment usually involves antibiotic therapy … Co., Cumberland Pharmaceuticals, Theravance Biopharma, Entasis … Pharmaceuticals, iNtRON Biotechnology, Durata Therapeutics, Cipher Pharmaceuticals, XBiotech, Basilea Pharmaceutica …
-
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript
13 Aug 2025 13:39 GMT
… Transcript August 12, 2025
Theravance Biopharma, Inc. beats … supported in our previous trials. In the prespecified … symptomatic despite currently available treatments such as midodrine … ampreloxetine prelaunch commercial and medical affairs activities. Share- …
-
Global Myeloproliferative Disorder Treatment Market is Expected to Showcase an Incremental Growth at a CAGR of ~5% by 2032 | DelveInsight
06 Aug 2025 17:00 GMT
… Drug Administration (FDA) approved OJJAARA (momelotinib) for the treatment … biotech firms and large pharmaceutical … Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics … , Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda …
-
Theravance Biopharma To Report Second Quarter 2025 Financial Results On August 12, 2025
28 Jul 2025 11:20 GMT
… Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines … FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment … information, please visit .
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross…
About
© 1995-2025